Thymulin Analog (PAT) vs Thymalin — Peptide Comparison

Thymulin Analog (PAT) vs Thymalin — Peptide Comparison Thymulin Analog (PAT) vs Thymalin — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Thymulin Analog (PAT) 1 mcg–50 mcg mcg Thymalin 5–10 mg Frequency Once daily Administration Intraperitoneal injection Intramuscular injection Cycle Length Ongoing/indefinite 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Strong human trials (Phase 3 or FDA approved) Limited human trials Efficacy Pain Relief Anti-Inflammatory Neuroprotection Immune Restoration Longevity Support Disease Prevention Technical Data Molecular Formula C37H62N12O15 Molecular Weight 858.9 Da Half-Life Effects peak at 1-2 hours; diminish by 3-4 hours post-single dose Bioavailability Effective via intraperitoneal and intracerebroventricular routes in preclinical models CAS Number Not assigned Complex mixture; active dipeptide EW: C16H19N3O5 Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da Not precisely characterized for complex; immune effects persist weeks post-administration High via intramuscular or subcutaneous injection 63958-90-7 Protocols standard 5-10 mg reconstituted in saline 5-10 day course, often repeated every 6 months Reflects the Russian clinical course used in immune-restoration and gerontology protocols, typically 10 mg IM daily for 5-10 days [1]. advanced 10 mg Up to 20 day course, repeated every 6 months Subcutaneous administration is used in community practice at the same 10 mg daily dosing; longer 20-day courses are described for cyclical immune support [1]. Applications Neuropathic pain research Thymulin Analog (PAT) is particularly well-suited for individuals focused on neuropathic pain research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-inflammatory therapy development Thymulin Analog (PAT) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Novel analgesic mechanism investigation Thymulin Analog (PAT) is particularly well-suited for individuals focused on novel analgesic mechanism investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Cytokine-mediated pain pathway studies Thymulin Analog (PAT) is particularly well-suited for individuals focused on cytokine-mediated pain pathway studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Aging Adults Seeking Immune Support Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy. Longevity and Anti-Aging Protocols Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols. Seasonal Illness Prevention Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward. Safety Profile Common Injection Site Reaction Transient Immune Modulation Mild Sedation Short Duration of Action Uncommon Potential Immune Suppression CNS Effects with Central Administration Serious Unintended Immune Stimulation No side effects in most patients Mild injection site reaction Transient low-grade fever Mild flu-like symptoms Temporary headache Severe allergic reaction Research Status FDA Status Research compound Safety Overview Thymulin Analog (PAT) is a synthetic 9-amino acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) that is a research compound ONLY—NOT approved for human use. No serious adverse effects have been documented in extensive preclinical studies spanning 17+ years. However, this is a critical limitation: all data comes from animal models (primarily rats and mice). Zero completed human clinical trials exist. The peptide has not undergone human Phase 1 safety testing. No manufactured batches meet pharmaceutical standards. PAT's primary mechanism—alpha-7 nAChR potentiation—could theoretically affect multiple organ systems, but human safety data is absent. As an immune-modulating compound, prolonged high-dose use could theoretically suppress protective immunity, though animal studies show no adverse effects at therapeutic doses. Individual responses in humans are completely unknown. Contraindications xNot approved for human use xPotential immune modulation concerns with chronic use xUnknown drug-drug interactions xPregnancy and lactation (insufficient safety data) Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods. xActive thymic tumors or malignancies xKnown hypersensitivity to animal-derived peptide products xPregnancy and breastfeeding (insufficient safety data) xSevere uncontrolled autoimmune disease without medical supervision Decision Guide Choose Thymulin Analog (PAT) if... Neuropathic pain research Anti-inflammatory therapy development Novel analgesic mechanism investigation Cytokine-mediated pain pathway studies Choose Thymalin if... Immune system restoration in aging adults Longevity and healthy aging support Reducing infection frequency and severity Multi-system health optimization